- Home
- SD vs NMRA Comparison
SD vs NMRA Comparison
Compare SD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SD | NMRA |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.7M | 554.0M |
| IPO Year | 2006 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SD | NMRA |
|---|---|---|
| Price | $14.91 | $1.91 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $15.00 | $7.50 |
| AVG Volume (30 Days) | 272.8K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 12.43 | 5.23 |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | $29.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.52 | $0.66 |
| 52 Week High | $18.45 | $3.65 |
Technical Indicators
Market Signals| Indicator | SD | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 40.55 |
| Support Level | $13.66 | $1.81 |
| Resistance Level | $15.73 | $2.22 |
| Average True Range (ATR) | 0.44 | 0.22 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 33.99 | 14.86 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.